🚀 I'm excited and proud to share the update of the #STARTNEWERA phase II trial! 📢 Now in press on @IJROBP the 5️⃣-y survival and safety of #SAbR in unresectable LA-NSCLC 👫 unfit for concurrent RT-ChT:focus on patterns of local recurrence! https://t.co/zDq74WXuaO @PaolaAnselmo7

Thanks @IJROBP Editorial Team,Editor in Chief @sueyom for continuing believe in our trial giving us great opportunity to publish it in @IJROBP We are honored! Other great step for #SAbR LA-NSCLC Thanks patients&families #STARTNEWERA Team @PaolaAnselmo7 Michelina Casale @gusviani

➡️ Take-home: Delivering ≥40 Gy/5 with VMAT-SAbR (with SIB/SIP) is safe, effective & paradigm-shifting for frail LA-NSCLC. A new era begins. https://t.co/qqsnLp4rJK #RadOnc #LungCancer #SAbR

💡 Impact SAbR in 5 fractions provides durable control, minimal toxicity, and a radical alternative when chemo-RT is unsafe — while preserving IO & salvage options.

📊 Results • 5-yr OS: 46% • 5-yr PFS: 26% • No ≥G3 late toxicity • SCC & <40 Gy → ↑ local recurrence • Re-SAbR feasible in salvage

🏥 Methods • Phase II, 50 pts (median age 73) • VMAT-SAbR: 45 Gy tumor / 40 Gy nodes in 5 fractions • Planning with SIB (simultaneous integrated boost) & SIP (simultaneous integrated protection) • Some received induction chemo ± IO consolidation

🔎 The Gap Until now, frail stage III NSCLC pts unfit for concurrent chemo-RT had no radical option beyond palliative RT. Prospective long-term data on SAbR in this setting were missing.

START the NEW ERA 5-year outcomes of SAbR in frail LA-NSCLC 🚭A new radical option when chemo-RT is not feasible. @OncoAlert @FabArcidiacono8 @PaolaAnselmo7 🙏 Grateful to Fabio Arcidiacono & Paola Anselmo for inviting me to be part of this team effort that pushes the

Paola Anselmo: Pablo Muñoz Schuffenegger on SAbR in Oligometastatic NSCLC

#WCLC25 a honor to present #STARTNEWERA & #STARTNEWERAOLIGO 🇮🇹trials 1️⃣OC:ChT➡️#SAbR➡️#IO 35👫 unresectable LA-NSCLC 2️⃣OC:#SAbR 90👫#oligoP NSCLC #IO #TT era 3️⃣Poster:salvage #SAbR 31👫 thoracic nodal recurrence 4️⃣Poster discussed:update #STARTNEWERA 101👫 unresectable LA-NSCLC

My favorite part of the START-NEW-ERA study is that they use both SIB and SIP. Simultaneous integrated boost and Simultaneous integrated protection #WCLC25

@DrewMoghanaki Thanks @DrewMoghanaki 🚀 We believe the real "secret" behind the #STARTNEWERA trial is the synergy of #SIB and #SIP 👉 However here’s the twist: our #SIP is adapted to make the difference! 😉 @PaolaAnselmo7

Chemo or Not? RT Alone Holds Strong After Hysterectomy 🚨 @OncoAlert 🎯 316 pts, stage IB–IIA, randomized RT vs CRT (NRG/GOG-263) 📊 3y RFS: 88.5% (CRT) vs 85.4% (RT) → NS 📊 OS trend favoring CRT, but no significance ⚠️ Toxicity: 43% vs 15% (CRT ↑) ✅ RT alone highly

🔥 PORTEC-3: Redefining Adjuvant Therapy in High-Risk Endometrial Cancer 🔥 @OncoAlert 🎯 Objective Test if adding chemotherapy to pelvic RT improves survival vs RT alone in high-risk EC. 🏥 Methods •Phase III RCT, n=660, 103 centers, 7 countries •Arm A: EBRT 48.6 Gy/1.8 Gy

🔥 PCS-9: SBRT + ENZA Doubles Disease Control in Oligometastatic CRPC @OncoAlert @dr_cury 🎯 Objective • Evaluate whether adding SBRT to ADT + enzalutamide ⬆️ outcomes in oligometastatic CRPC (≤5 mets) 🏥 Methods • Ph 2, randomized, 13 Canadian centers. • 100 men with

https://t.co/j6u5enwT7E

🔬 Can 20 Fractions Compete? Early Results from HYPOCx-iRex Trial A phase II RCT exploring hypofractionation in LACC. Promising? Let’s dive in 🎯 Objective Evaluate safety & efficacy of 44 Gy/20F hypofractionated chemoradiation vs 45 Gy/25F 🏥 Methods • Open-label RCT (n=40)

https://t.co/Q8ZH0EBfAD

🧠 Pre-Op FSRT vs Post-Op FSRT – New Data on Brain Met Resections! @OncoAlert 🎯 Objective Test if pre-op FSRT improves outcomes vs post-op FSRT in resected brain mets. 🏥 Methods •458 pts / 534 mets •27 Gy/3 fx or 30 Gy/5 fx •LINAC/GK, 2–3 mm margins 📊 Results

🎯 3-Year OS Nearly Doubled: ACCORD Trial Delivers! @OncoAlert 🎯 Objective Evaluate if adjuvant camrelizumab + capecitabine + ☢️ ⬆️ outcomes vs. observation after curative 🔪 for extrahepatic cholangiocarcinoma (EHC) & gallbladder cancer (GBC). 🏥 Methods •Design: ACCORD RCT